We are developing a disruptive gene therapy platform addressing the root causes of neurodegenerative conditions through a unique multifactorial approach
Scroll down
Our groundbreaking therapeutic approach is linked to extensive research carried out at the Cajal Institute in Madrid, affiliated with the Spanish National Research Council (CSIC).
Our groundbreaking therapeutic approach is linked to extensive research carried out at the Cajal Institute in Madrid, affiliated with the Spanish National Research Council (CSIC).
We’re developing gene therapies aimed at addressing neurodegenerative conditions, reinstating biological processes that have been impacted by the pathogenic phosphorylation of E2F4.
The scientific team has members with over 30 years of experience in neuroscience, along with executives from biopharmaceutical companies as partners.
